You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Medtronic
Johnson and Johnson
Express Scripts
Baxter

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

DOXAZOSIN MESYLATE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Doxazosin Mesylate patents expire, and when can generic versions of Doxazosin Mesylate launch?

Doxazosin Mesylate is a drug marketed by Accord Hlthcare, Actavis Elizabeth, Ani Pharms Inc, Apotex, Dava Pharms Inc, Genpharm, Heritage Pharma, Ivax Sub Teva Pharms, Mylan, Nesher Pharms, Pliva, Teva, Upsher Smith Labs, Watson Labs Inc, Yaopharma Co Ltd, and Zydus Pharms. and is included in seventeen NDAs.

The generic ingredient in DOXAZOSIN MESYLATE is doxazosin mesylate. There are fourteen drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.

US ANDA Litigation and Generic Entry Outlook for Doxazosin Mesylate

A generic version of DOXAZOSIN MESYLATE was approved as doxazosin mesylate by APOTEX on October 18th, 2000.

  Start Trial

Drug patent expirations by year for DOXAZOSIN MESYLATE
Drug Prices for DOXAZOSIN MESYLATE

See drug prices for DOXAZOSIN MESYLATE

Drug Sales Revenue Trends for DOXAZOSIN MESYLATE

See drug sales revenues for DOXAZOSIN MESYLATE

Recent Clinical Trials for DOXAZOSIN MESYLATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
PfizerN/A
National Heart, Lung, and Blood Institute (NHLBI)Phase 2
University of Minnesota - Clinical and Translational Science InstitutePhase 2

See all DOXAZOSIN MESYLATE clinical trials

Pharmacology for DOXAZOSIN MESYLATE
Medical Subject Heading (MeSH) Categories for DOXAZOSIN MESYLATE
Paragraph IV (Patent) Challenges for DOXAZOSIN MESYLATE
Tradename Dosage Ingredient NDA Submissiondate
CARDURA TABLET;ORAL doxazosin mesylate 019668

US Patents and Regulatory Information for DOXAZOSIN MESYLATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pliva DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 075750-001 Jun 8, 2001 AB RX No No   Start Trial   Start Trial   Start Trial
Ivax Sub Teva Pharms DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 075453-004 Oct 18, 2000 DISCN No No   Start Trial   Start Trial   Start Trial
Teva DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 075353-003 Jan 12, 2001 DISCN No No   Start Trial   Start Trial   Start Trial
Watson Labs Inc DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 075426-004 Oct 18, 2000 DISCN No No   Start Trial   Start Trial   Start Trial
Teva DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 075353-001 Jan 12, 2001 DISCN No No   Start Trial   Start Trial   Start Trial
Teva DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 075536-003 Oct 18, 2000 AB RX No No   Start Trial   Start Trial   Start Trial
Upsher Smith Labs DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 209013-003 Apr 17, 2018 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Harvard Business School
AstraZeneca
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.